tirzepatide trial results In the SURMOUNT-5 phase 3b involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body weight and waist circumference. Full trial and Research Summary Tirzepatide Demonstrates Cardioprotective Effects in

If you accidentally make contact with a non-sterile surface, discard that needle or syringe and use a fresh one from sealed packaging

Cost and Accessibility: New drugs often come with high price tags, and access can be limited by insurance coverage and healthcare policies

Glutathione is our bodys most abundant antioxidant, playing a critical role in protecting the body from oxidative stress

semaglutide, people without type 2 diabetes who took: Tirzepatide experienced an average weight loss of 20.2% after 72 weeks (~16.5 months) Semaglutide experienced an average weight loss of 13.7%after 72 weeks (~16.5 months) A 2024 cohort study of people with obesity or overweight outside of a clinical trial also compared tirzepatide vs